What is the next dose of Wegovy (semaglutide) after 1.7mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Wegovy Dosing After 1.7mg

The next dose of Wegovy after 1.7mg is 2.4mg once weekly, which is the target maintenance dose for weight management.

Standard Wegovy Titration Schedule

The FDA-approved titration schedule for Wegovy (semaglutide for obesity) follows a specific escalation pattern to minimize gastrointestinal side effects while reaching the therapeutic dose 1, 2:

  • 0.25mg once weekly for 4 weeks (initial dose)
  • 0.5mg once weekly for 4 weeks
  • 1.0mg once weekly for 4 weeks
  • 1.7mg once weekly for 4 weeks
  • 2.4mg once weekly (target maintenance dose) 3, 4

After completing 4 weeks at the 1.7mg dose, you should advance to 2.4mg once weekly, which is the final therapeutic dose for weight management 2, 4.

Why 2.4mg is the Target Dose

The STEP clinical trial program demonstrated that 2.4mg once weekly is the optimal dose for weight management, achieving mean weight loss of 14.9%-17.4% over 68 weeks 4. This dose showed:

  • 69%-79% of participants achieved ≥10% weight loss (versus 12%-27% with placebo) 4
  • 51%-64% achieved ≥15% weight loss (versus 5%-13% with placebo) 4
  • Superior improvements in cardiometabolic risk factors compared to lower doses 2

Important Considerations

Gradual titration is essential - the 16-week escalation schedule allows gastrointestinal tolerance to develop and minimizes adverse events like nausea and diarrhea 5, 1.

Long-term use is necessary - participants who discontinued semaglutide regained significant weight (mean regain of 11.6% of lost weight after cessation), indicating lifelong treatment may be required 6.

If doses are missed: If you miss 3 or more consecutive doses at the 1.7mg level, consider restarting the titration schedule rather than jumping directly to 2.4mg 7, 5.

Common Pitfall to Avoid

Do not remain at 1.7mg indefinitely unless there are specific tolerability issues - this is a titration dose, not a maintenance dose 3. The clinical trial data supporting weight loss efficacy is based on reaching and maintaining the 2.4mg dose 2, 4.

References

Research

Clinical review of subcutaneous semaglutide for obesity.

Journal of clinical pharmacy and therapeutics, 2022

Research

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

The New England journal of medicine, 2021

Research

Wegovy (semaglutide): a new weight loss drug for chronic weight management.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022

Guideline

Ozempic Dosing and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Rybelsus Administration and Titration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.